Mangoceuticals shares are trading higher after the company announced that it secured a strategic partnership with the International Society of Frontier Life Sciences and Technology for the distribution of its products in China and the Asia Pacific region and Latin America.

7/11/24 8:53:22 AM ET

Misc Health and Biotechnology Services

Health Care

Get the next $MGRX alert in real time by email

Get the next $MGRX alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$MGRX

Date	Price Target	Rating	Analyst

More analyst ratings

$MGRX
Press Releases

Fastest customizable press release news feed in the world

View All

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions and its partner IntraMont Technologies, Inc. today announced the filing of a Patent Cooperation Treaty (PCT) international application (P-641039-PC) on February 26, 2026, to secure broad global patent protection for the antiviral animal feed and drinking water additive technology that powers MGX-0024. This PCT filing directly extends the intellectual property portfolio supporting the results

3/6/26 4:00:00 PM ET

$MGRX

Misc Health and Biotechnology Services

Health Care

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, today announced new data from its proprietary antiviral compound MGX-0024. A technical report issued by partner IntraMont Technologies in late 2025, combined with the final signed report from the ICAR-National Institute of High Security Animal Diseases (NIHSAD), Bhopal, supports MGX-0024's potential to reduce respiratory disease impacts in commercial poultry settings and provide meaningful ea

2/23/26 4:05:00 PM ET

$MGRX

Misc Health and Biotechnology Services

Health Care

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (the "Company" or "MangoRx"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that MangoRx has experienced initial success for its newly launched all-inclusive injectable Testosterone Replacement Therapy (TRT) treatment program priced at $99 per month. The new TRT offer includes all doctor visits and medical consultations, lab work and analysis, and the medication to the extent prescribe

2/19/26 4:05:00 PM ET

$MGRX

Misc Health and Biotechnology Services

Health Care

Mangoceuticals shares are trading higher after the company announced that it secured a strategic partnership with the International Society of Frontier Life Sciences and Technology for the distribution of its products in China and the Asia Pacific region and Latin America.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$MGRX

Mangoceuticals shares are trading higher after the company announced that it secured a strategic partnership with the International Society of Frontier Life Sciences and Technology for the distribution of its products in China and the Asia Pacific region and Latin America.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$MGRX

$MGRX
Press Releases

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

$MGRX
SEC Filings

Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Mangoceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$MGRX
Insider Trading

CFO Johnston Eugene M sold $3,884 worth of shares (3,333 units at $1.17), decreasing direct ownership by 3% to 120,000 units (SEC Form 4)

CFO Johnston Eugene M sold $5,975 worth of shares (5,000 units at $1.20), decreasing direct ownership by 4% to 123,333 units (SEC Form 4)

CFO Johnston Eugene M sold $11,280 worth of shares (10,000 units at $1.13), decreasing direct ownership by 7% to 128,333 units (SEC Form 4)

$MGRX
Leadership Updates

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

$MGRX
Financials

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

$MGRX
Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Mangoceuticals Inc.

SEC Form SC 13D/A filed by Mangoceuticals Inc. (Amendment)

Mangoceuticals shares are trading higher after the company announced that it secured a strategic partnership with the International Society of Frontier Life Sciences and Technology for the distribution of its products in China and the Asia Pacific region and Latin America.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $MGRX

Mangoceuticals shares are trading higher after the company announced that it secured a strategic partnership with the International Society of Frontier Life Sciences and Technology for the distribution of its products in China and the Asia Pacific region and Latin America.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $MGRX

$MGRX Press Releases

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

$MGRX SEC Filings

Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Mangoceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$MGRX Insider Trading

CFO Johnston Eugene M sold $3,884 worth of shares (3,333 units at $1.17), decreasing direct ownership by 3% to 120,000 units (SEC Form 4)

CFO Johnston Eugene M sold $5,975 worth of shares (5,000 units at $1.20), decreasing direct ownership by 4% to 123,333 units (SEC Form 4)

CFO Johnston Eugene M sold $11,280 worth of shares (10,000 units at $1.13), decreasing direct ownership by 7% to 128,333 units (SEC Form 4)

$MGRX Leadership Updates

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

$MGRX Financials

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

$MGRX Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Mangoceuticals Inc.

SEC Form SC 13D/A filed by Mangoceuticals Inc. (Amendment)

Recent Analyst Ratings for
$MGRX

Recent Analyst Ratings for
$MGRX

$MGRX
Press Releases

$MGRX
SEC Filings

$MGRX
Insider Trading

$MGRX
Leadership Updates

$MGRX
Financials

$MGRX
Large Ownership Changes